CatK, an attractive therapeutic target for diseases with excessive bone resorption such as osteoporosis and osteoarthritis26–32, is a major lysosomal protease that accounts for 98% of total cysteine protease activity in osteoclasts and is responsible for the degradation of bone matrix proteins49. Here, CTSB is linked to osteoporosis.